MA37866B1 - Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur - Google Patents
Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleurInfo
- Publication number
- MA37866B1 MA37866B1 MA37866A MA37866A MA37866B1 MA 37866 B1 MA37866 B1 MA 37866B1 MA 37866 A MA37866 A MA 37866A MA 37866 A MA37866 A MA 37866A MA 37866 B1 MA37866 B1 MA 37866B1
- Authority
- MA
- Morocco
- Prior art keywords
- indazole
- pain
- treatment
- diaza
- aza
- Prior art date
Links
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical class C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 title 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne un composé de formule (i) suivante ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, un tautomère de celui-ci ou un stéréo-isomère ou un mélange de stéréo-isomères de celui-ci dans des proportions quelconques, tel qu'un mélange d'énantiomères, notamment un mélange racémique, destiné à être utilisé dans le traitement de la douleur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305922.2A EP2689778A1 (fr) | 2012-07-27 | 2012-07-27 | Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur |
| PCT/EP2013/065907 WO2014016433A1 (fr) | 2012-07-27 | 2013-07-29 | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37866A1 MA37866A1 (fr) | 2016-05-31 |
| MA37866B1 true MA37866B1 (fr) | 2016-12-30 |
Family
ID=48948392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37866A MA37866B1 (fr) | 2012-07-27 | 2015-02-23 | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9381195B2 (fr) |
| EP (2) | EP2689778A1 (fr) |
| JP (2) | JP6456823B2 (fr) |
| KR (1) | KR102120505B1 (fr) |
| CN (1) | CN104684554B (fr) |
| AU (1) | AU2013294920B2 (fr) |
| BR (1) | BR112015001502B1 (fr) |
| CA (1) | CA2879595C (fr) |
| CY (1) | CY1118478T1 (fr) |
| DK (1) | DK2877177T3 (fr) |
| ES (1) | ES2612349T3 (fr) |
| HR (1) | HRP20170104T1 (fr) |
| HU (1) | HUE032919T2 (fr) |
| IL (1) | IL236917A (fr) |
| LT (1) | LT2877177T (fr) |
| MA (1) | MA37866B1 (fr) |
| MX (1) | MX363605B (fr) |
| MY (1) | MY183398A (fr) |
| NZ (1) | NZ705253A (fr) |
| PL (1) | PL2877177T3 (fr) |
| PT (1) | PT2877177T (fr) |
| RS (1) | RS55646B1 (fr) |
| RU (1) | RU2640046C2 (fr) |
| SI (1) | SI2877177T1 (fr) |
| TN (1) | TN2015000034A1 (fr) |
| UA (1) | UA116107C2 (fr) |
| WO (1) | WO2014016433A1 (fr) |
| ZA (1) | ZA201501209B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140309T1 (hr) | 2008-10-22 | 2014-05-09 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| EP2689778A1 (fr) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur |
| WO2015143652A1 (fr) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | Inhibiteurs de la kinase trka, compositions et méthodes associées |
| MX386826B (es) | 2014-10-06 | 2025-03-19 | Apm Therapeutics 1 Inc | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística |
| JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形 |
| WO2016096709A1 (fr) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Dérivés hétérocycliques modulant l'activité de certaines protéines kinases |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| WO2018049271A1 (fr) * | 2016-09-09 | 2018-03-15 | Flx Bio, Inc. | Modulateurs des récepteurs de la chimiokine et leurs utilisations |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018079759A1 (fr) * | 2016-10-31 | 2018-05-03 | 塩野義製薬株式会社 | Hétérocycle fusionné ayant une activité inhibitrice de trka et dérivé carbocycle fusionné |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN112313232B (zh) * | 2018-05-02 | 2024-03-08 | Jw中外制药公司 | 新型杂环衍生物 |
| KR102129114B1 (ko) * | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
| EP3725777A1 (fr) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- et pyrido-pyrazoles en tant qu`inhibiteurs de protéine kinase |
| CN110105356B (zh) * | 2019-05-31 | 2022-04-01 | 四川国康药业有限公司 | 一种氮杂吲哚类化合物及其制备方法和用途 |
| CN121358733A (zh) * | 2023-05-24 | 2026-01-16 | 长春金赛药业有限责任公司 | Fgfr2/3选择性抑制剂、药物组合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199902301T2 (xx) | 1997-03-19 | 1999-12-21 | Basf Aktiengesellschaft | Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�. |
| EP1215208B1 (fr) | 1997-10-27 | 2006-07-12 | Agouron Pharmaceuticals, Inc. | Dérivées de 4-aminothiazole, leur préparation et leur utilisation comme inhibiteurs des kinases cycline-depenents |
| PT1292586E (pt) | 2000-06-22 | 2004-11-30 | Pfizer | Processo para a preparacao de pirazolopirimidinonas |
| SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| WO2007023110A2 (fr) * | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | Inhibiteurs de la map-kinase p38 et ses methodes d'utilisation |
| CA2657287A1 (fr) | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | Composes de 1-hydroxy naphtyridine en tant qu'agents anti-vih |
| EP2120932B1 (fr) * | 2006-12-20 | 2014-07-09 | Nerviano Medical Sciences S.r.l. | Dérivés de l'indazole en tant qu'inhibiteurs des kinases pour le traitement du cancer |
| WO2008089307A2 (fr) * | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer |
| WO2008112695A2 (fr) * | 2007-03-12 | 2008-09-18 | Irm Llc | Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci |
| US8299057B2 (en) | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| ES2630026T3 (es) * | 2008-12-18 | 2017-08-17 | Nerviano Medical Sciences S.R.L. | Derivados indazólicos sustituidos activos como inhibidores de cinasa |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| EP2689778A1 (fr) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur |
-
2012
- 2012-07-27 EP EP12305922.2A patent/EP2689778A1/fr not_active Withdrawn
-
2013
- 2013-07-29 SI SI201330496A patent/SI2877177T1/sl unknown
- 2013-07-29 DK DK13745813.9T patent/DK2877177T3/en active
- 2013-07-29 ES ES13745813.9T patent/ES2612349T3/es active Active
- 2013-07-29 MY MYPI2015700206A patent/MY183398A/en unknown
- 2013-07-29 BR BR112015001502-6A patent/BR112015001502B1/pt active IP Right Grant
- 2013-07-29 PT PT137458139T patent/PT2877177T/pt unknown
- 2013-07-29 RS RS20170095A patent/RS55646B1/sr unknown
- 2013-07-29 RU RU2015106434A patent/RU2640046C2/ru active
- 2013-07-29 WO PCT/EP2013/065907 patent/WO2014016433A1/fr not_active Ceased
- 2013-07-29 JP JP2015523576A patent/JP6456823B2/ja active Active
- 2013-07-29 HU HUE13745813A patent/HUE032919T2/hu unknown
- 2013-07-29 KR KR1020157004735A patent/KR102120505B1/ko not_active Expired - Fee Related
- 2013-07-29 NZ NZ705253A patent/NZ705253A/en unknown
- 2013-07-29 CA CA2879595A patent/CA2879595C/fr active Active
- 2013-07-29 EP EP13745813.9A patent/EP2877177B1/fr active Active
- 2013-07-29 CN CN201380049411.3A patent/CN104684554B/zh active Active
- 2013-07-29 US US14/417,507 patent/US9381195B2/en active Active
- 2013-07-29 AU AU2013294920A patent/AU2013294920B2/en not_active Ceased
- 2013-07-29 UA UAA201501614A patent/UA116107C2/uk unknown
- 2013-07-29 PL PL13745813T patent/PL2877177T3/pl unknown
- 2013-07-29 HR HRP20170104TT patent/HRP20170104T1/hr unknown
- 2013-07-29 MX MX2015001009A patent/MX363605B/es unknown
- 2013-07-29 LT LTEP13745813.9T patent/LT2877177T/lt unknown
-
2015
- 2015-01-23 TN TNP2015000034A patent/TN2015000034A1/fr unknown
- 2015-01-25 IL IL236917A patent/IL236917A/en active IP Right Grant
- 2015-02-23 ZA ZA2015/01209A patent/ZA201501209B/en unknown
- 2015-02-23 MA MA37866A patent/MA37866B1/fr unknown
-
2017
- 2017-01-23 CY CY20171100091T patent/CY1118478T1/el unknown
-
2018
- 2018-10-24 JP JP2018200317A patent/JP6732855B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA42341B2 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| MA46038A (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA38358A1 (fr) | Formulations de composés organiques | |
| MA39983A (fr) | Dérivés de carboxamide | |
| SA520420382B1 (ar) | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1 | |
| MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
| MA38307A1 (fr) | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale | |
| FR3047665B1 (fr) | Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees | |
| MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant | |
| PH12021550248A1 (en) | Borate of azetidine derivative | |
| MA50899B1 (fr) | Composés utiles pour l'inhibition de cdk7 | |
| MA38191A1 (fr) | Composés tricycliques pour inhiber le canal cftr | |
| MA38599A1 (fr) | Nouveaux dérivés pyrazolopyrrolidine et leur utilisation dans le traitement de maladies |